Fast Radial Pharmaco-invasive Strategy In ST Elevation Myocardial Infarction Trial

NCT ID: NCT04300582

Last Updated: 2020-03-31

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: NA
• Total Enrollment: 120 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2019-12-13
• Study Completion Date: 2021-08-31

Brief Summary

INTRODUCTION: The pharmaco-invasive strategy is a safe alternative to primary percutaneous coronary intervention (PCI) in patients with ST elevation acute myocardial infarction, who cannot be in the cathlab in less than 120 minutes. However, previous studies of this strategy used the femoral artery as the main vascular access. Current studies show that the use of the radial artery in cases of acute myocardial infarction minimizes the risk of bleeding and mortality. Therefore, in the scenario where vascular access through the forearm vessels is recommended, the best timing to perform cardiac catheterization in the pharmaco-invasive strategy is not known.

OBJECTIVE: To compare the 24-hour hemoglobin drop (acute anemia) between the fast pharmaco-invasive strategy (within 3 hours) and the standard pharmaco-invasive strategy (3 to 24 hours) in patients with acute myocardial infarction (AMI) by coronary occlusion treated in Sancta Maggiore hospitals in São Paulo and underwent to cardiac catheterization through the forearm vessels.

METHOD: A prospective, randomized, multicenter study will be conducted in which 120 subjects will be randomly divided for fast and standard cardiac catheterization (1: 1). Stent implantation in the culprit vessel will be performed. The primary objective is to assess whether the fast cardiac catheterization is non-inferior to the standard strategy for a hemoglobin (Hb) drop within 24 hours. Considering in the control group an average drop of Hb 0.6 ± 1g / dl and that a drop greater than 3 g/dL of Hb is related to unfavorable clinical outcome, using a two-tailed alpha of 0.05 and a power of 90% to test the non-inferiority of the fast strategy with respect to standard strategy, each group will require 60 patients, totaling 120 individuals to include. However, if Hb fall in the fast strategy is greater than 3 g/dL and this result does not reproduce in the standard strategy, the study will allow us to show the superiority of the standard approach (between 3 and 24 hours).

Detailed Description

The FARAD MI will be a randomized, multicenter prospective study will be conducted. Patients with the diagnosis of ST-segment elevation acute myocardial infarction treated at the Sancta Maggiore Emergency Departments who have been thrombolyzed and aged up to 80 years will be included. After thrombolysis, patients will be immediately transferred to the Sancta Maggiore Hospital Itaim Unit and should arrive less than 3 hours after thrombolytic completion. When they arrive at the Interventional Cardiology Department, they will be explained about the study and offered to participate in the trial with consequent signature of the informed consent form. Thereafter, electrocardiogram and blood collection will be performed for laboratory tests, including hemoglobin, and patients will be randomized (1:1) to fast pharmaco-invasive strategy (within 3 hours of thrombolytic completion) and standard pharmaco-invasive strategy (3-24 hours). They will stay in the Interventional Cardiology Department until the procedure is performed and then the in-hospital care will be continued. Twenty-four hours after admission to the Interventional Cardiology Department, a new hemoglobin collection will be performed. Patients who refuse to participate in the trial will not have any harm in the treatment of acute coronary syndrome. Patients will receive standard clinical therapy, including dual antiplatelet therapy. Stent implantation will be performed in the culprit vessel by AMI. The treatment of residual coronary artery disease (coronary lesions with obstruction greater than 70% or with evidence of ischemia) will be discussed with the Clinical Cardiology team during hospitalization.

The following data will be collected: gender, age, ST-segment elevation location on the electrocardiogram (ECG), symptoms duration, time from first evaluation to ECG (door-to-ECG), time from first evaluation until thrombolytic administration (door-to-needle), thrombolytic used, medications administered at the origin unit, time between the end of thrombolytic and the beginning of cardiac catheterization, type of procedure (diagnosis and / or intervention), date and time of procedure, access site, radiation dose, contrast volume, associated comorbidities, laboratory, weight, height, BMI, coronary artery disease pattern (Syntax Score), vessel culprit for AMI, type and size of stent used, successful intervention, coronary flow at the end of the procedure (TIMI), angioplasty technique, residual coronary artery disease approach, bleeding (BARC), major cardiovascular adverse events (MACE), any cause and cardiovascular death. The hemoglobin of the patient's admission to the Interventional Cardiology Department and its variation after 24 hours will be evaluated. If red blood cell transfusion is required, pre-transfusion hemoglobin will be considered for evaluation.

Data from each patient will be registered in the REDCap platform in a electronic case report form (CRF) and will be submitted to statistical analysis using the Statistical Package for the Social Sciences (SPSS) 24 program. The REDCap has some important characteristics such as role-based authentication and security; real-time data validation and integrity checking; data assignment and audit capability; storage and sharing of protocols; central storage and backup of data and data export in formats compatible with known analysis programs as Excel, SPSS, Statistical Analysis System (SAS), Stata, R software, among others. Data will be audited by an independent team from Prevent Senior's Institute of Education and Research.

Patients who have the following characteristics will not be included in this trial: contraindications to fibrinolytic therapy, such as active internal bleeding, clinical signs of acute aortic dissection, traumatic or prolonged cardiopulmonary resuscitation (> 10 minutes), head trauma in the last four weeks, history of intracranial neoplasia, ischemic stroke in the past year or previous haemorrhagic stroke, pregnancy, sustained severe hypertension (≥180 mmHg systolic pressure and / or ≥110 mmHg diastolic pressure), trauma or major surgery in the last four weeks, use of oral anticoagulants, history of liver or kidney failure; did not meet reperfusion criteria upon arrival at the Interventional Cardiology Service of the Sancta Maggiore Hospital Itaim Unit (no improvement in chest pain or reduction in ST-segment elevation below 50% after thrombolytic administration); having femoral access as the first choice for invasive stratification; bleeding complications prior to cardiac catheterization, such as important hematoma and stroke; acute pulmonary edema (dyspnea of cardiac etiology with increased respiratory effort, hypoxemia and / or desaturation); cardiogenic shock (systolic blood pressure below 90 mmHg associated with signs of tissue hypoperfusion, such as oliguria, altered level of consciousness, cyanosis, cold and wet extremities, or vasopressor drug use); do not accept to sign the consent form.

Patients will be studied according to the precepts of the Helsinki Declaration and the Nuremberg Code, respecting the Research Norms Involving Human Beings (National Health Council resolution: 466/12) of the National Health Council. The study will be explained to patients when they are admitted to the Interventional Cardiology Department of the Sancta Maggiore Itaim Hospital and will be required to sign the Informed Consent Form (ICF) before any invasive procedure is performed. Randomization will be performed through a specific site after signing the consent form. The project was approved by the Research Ethics Committee of the Prevent Senior Research Institute.

To perform the sample calculation, the study of Bertrand OF et al (2010) was used to evaluate the variation of hemoglobin (Hb) in 24 hours after coronary angioplasty by radial approach. The control group had a mean hemoglobin drop of 0.6 ± 1g / dL and there were worse outcomes in patients with a hemoglobin drop greater than 3g / dL. (22) Therefore, considering in the control group a mean Hb fall of 0.6 ± 1g / dl and a fall greater than 3 g/dL of Hb is related to an unfavorable clinical outcome, using a two-tailed alpha of 0.05 and a power of 90% to test the non-inferiority of the fast strategy over the standard strategy, each group will require 60 patients, totaling 120 individuals to be included. However, if the Hb drop in the fast strategy is greater than 3 g/dL and this result does not reproduce in the standard strategy, the study will allow us to show the superiority of the strategy between 3 and 24 hours.

An intention-to-treat assessment will be performed. Categorical variables will be presented as absolute numbers and percentages. Continuous variables will be presented as mean ± standard deviation or median (interquartile range) according to their distribution. The distribution evaluation of continuous variables will be tested with Shapiro-Wilk. For continuous variables, the Student's t-test (normal distribution) or Wilcoxon-rank (non-normal distribution) will be used according to their distribution. For categorical variables the Chi-square test will be used.

Conditions

ST-segment Elevation Myocardial Infarction (STEMI)

Keywords

stemi; thrombolysis; radial approach; acute coronary syndrome; pharmaco-invasive therapy; percutaneous coronary intervention

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Standard pharmaco-invasive strategy

Cardiac catheterization 3 to 24 hours after thrombolytic completion in STEMI patients.

Group Type: ACTIVE_COMPARATOR

Cardiac catheterization standard strategy

Intervention Type: PROCEDURE

Cardiac catheterization by forearm approach 3 to 24 hours after thrombolytic completion in STEMI patients

Fast pharmaco-invasive strategy

Cardiac catheterization less than 3 hours after thrombolytic completion in STEMI patients.

Group Type: EXPERIMENTAL

Cardiac catheterization fast strategy

Intervention Type: PROCEDURE

Cardiac catheterization by forearm approach within 3 hours after thrombolytic completion in STEMI patients

Interventions

Cardiac catheterization standard strategy

Cardiac catheterization by forearm approach 3 to 24 hours after thrombolytic completion in STEMI patients

Intervention Type: PROCEDURE

Cardiac catheterization fast strategy

Cardiac catheterization by forearm approach within 3 hours after thrombolytic completion in STEMI patients

Intervention Type: PROCEDURE

Eligibility Criteria

Inclusion Criteria

• ST elevation myocardial infarction
• Submitted to thrombolysis
• Interventional Cardiology Department arrival less than 3 hours after the end of thrombolytic

Exclusion Criteria

• Fibrinolytic therapy contraindication: active internal bleeding, clinical signs of acute aortic dissection, traumatic or prolonged cardiopulmonary resuscitation (> 10 minutes), head trauma in the last four weeks, history of intracranial neoplasia, ischemic stroke in the past year or previous haemorrhagic stroke, pregnancy, sustained severe hypertension (≥180 mmmHg systolic pressure and / or ≥110 mmHg diastolic pressure), trauma or major surgery in the last four weeks, use of oral anticoagulants, history of liver or kidney failure
• No reperfusion criteria when arriving at the Interventional Cardiology Department: no improvement in chest pain or reduction in ST-segment elevation below 50% after thrombolytic administration
• Femoral approach as the first choice for invasive stratification
• Bleeding complications before cardiac catheterization such as important hematoma and stroke
• Acute pulmonary edema: dyspnea of cardiac etiology with increased respiratory effort, hypoxemia and / or desaturation
• Cardiogenic shock: systolic blood pressure below 90 mmHg associated with signs of tissue hypoperfusion, such as oliguria, altered level of consciousness, cyanosis, cold and wet extremities, or vasopressor drug use

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 80 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

University of Sao Paulo General Hospital

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Bruno Faillace, MD

Role: PRINCIPAL_INVESTIGATOR

University of Sao Paulo General Hospital

Locations

Sancta Maggiore Hospital

São Paulo, , Brazil

Site Status: RECRUITING

Countries

Brazil

Central Contacts

Carlos Campos, MD, PhD

Role: CONTACT

Phone: +5511995006665

Email: carlosacampos1@gmail.com

Rodrigo Esper, MD, PhD

Role: CONTACT

Phone: +5511999869306

Email: dresper@hotmail.com

Facility Contacts

Carlos Campos, MD, PhD

Role: primary

Rodrigo Esper, MD, PhD

Role: backup

Other Identifiers

001

Identifier Type: -

Identifier Source: org_study_id